FIELD: oncology.
SUBSTANCE: group of inventions is provided concerning a method of treating a patient with cancer and envisaging administration of chloropromazine and pentamidine simultaneously or consecutively with interval within 14 days in quantities large enough to inhibit growth of the cancer, or in the form of pharmaceutical composition containing indicated agents in quantities, which jointly reduce proliferation of the indicated cancer cells. Pharmaceutical composition itself designed to indicated treatment and pharmaceutical kit are also disclosed. Proposed therapeutical agents separately do not show any antiproliferative effects.
EFFECT: achieved synergetic antiproliferative effect in absence of toxicity regarding normal cells.
17 cl, 1 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMBINATION CONTAINING TNO155 AND RIBOCICLIB | 2020 |
|
RU2813111C2 |
| DOSAGE FORMS OF HISTONE DEACETYLASE INHIBITOR IN COMBINATION WITH BENDAMUSTINE AND THEIR APPLICATION | 2011 |
|
RU2609833C2 |
| METHODS AND COMPOSITIONS FOR TREATING CANCER | 2009 |
|
RU2508116C2 |
| PHARMACEUTICAL COMBINATION COMPRISING INHIBITOR PHOSPHATYLENOSITOL 3-KINASES AND AROMATASE INHIBITOR | 2013 |
|
RU2651023C2 |
| COMBINED THERAPY WITH EZH2 INHIBITOR | 2018 |
|
RU2754131C1 |
| KAHALALIDE F | 2001 |
|
RU2292216C2 |
| NEW COMBINATION COMPRISING N-ACETYL-L-CYSTEINE AND ITS USE | 2012 |
|
RU2605287C2 |
| COMBINATION OF TRIFLURIDINE/TIPIRACIL HYDROCHLORIDE, ANTITUMOR PLATINUM COMPLEX, AND MODULATOR OF CONTROL POINTS OF IMMUNE RESPONSE | 2018 |
|
RU2778887C2 |
| THERAPEUTIC COMBINATIONS CONTAINING RAF INHIBITOR AND ERK INHIBITOR | 2017 |
|
RU2774612C2 |
| SYNERGIC COMBINATION OF PROTEASOME INHIBITOR AND VITAMIN K FOR INHIBITION OF GROWTH AND PROLIFERATION OF TUMOUR CELLS, PHARMACEUTICAL COMPOSITION AND THEREOF-BASED ANTI-TUMOUR MEDICATION | 2013 |
|
RU2563986C2 |
